We derived paclitaxel resistant cancer cells to ascertain if Bcl-2 expression is altered during the development of chemoresistance and to determine if Bcl-2 functional converting peptides can be used to selectively kill paclitaxel resistant lung cancer cells. Here, BCL2 is linked to lung cancer.